Gastrointestinal hormone measurably improved symptoms of non-alcoholic fatty liver disease

By EASL March 15,2018

Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.

To read the full article, visit: ScienceDaily